Levothyroxine Bioequivalence To Be Discussed At FDA Public Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
Scheduling the event suggests FDA is re-evaluating its position on the interchangeability of the drug class. Announcement of the May 23 meeting comes nearly one year after the agency approved a number of equivalence claims for levothyroxine sodium products.
You may also be interested in...
FDA Solicits Bids For Levothyroxine Stability Testing
Some manufacturers have been unable to demonstrate that their products have a two-year shelf life, the agency said.
FDA Solicits Bids For Levothyroxine Stability Testing
Some manufacturers have been unable to demonstrate that their products have a two-year shelf life, the agency said.
"Orange Book" Supplement Highlights Levothyroxine Equivalence Codes
Supplement also adds a Genpharm levothyroxine sodium ANDA to the "Orange Book" chart.